The Challenge of the Blood-Brain Barrier
One of the greatest hurdles in psychotropic pharmacology is the highly selective blood-brain barrier (BBB). This protective layer of endothelial cells, tight junctions, and efflux pumps rigorously controls what enters the brain from the bloodstream, blocking over 98% of small-molecule drugs and nearly all large-molecule therapeutics. Furthermore, even when a drug crosses the BBB, its distribution is often global, affecting both target and off-target circuits, leading to side effects. The Institute's Advanced Delivery Systems Lab is dedicated to engineering sophisticated solutions to these problems, moving beyond simple pills and injections to create smart, targeted, and controllable delivery platforms.
Nanotechnology: Trojan Horses for the Brain
Nanocarriers—particles in the size range of 1-100 nanometers—are being designed as 'Trojan horses' to ferry drugs across the BBB. Our research focuses on several types:
- Lipid-Based Nanoparticles (e.g., Liposomes): These spherical vesicles can encapsulate both hydrophilic and hydrophobic drugs. By decorating their surface with ligands that bind to receptors highly expressed on BBB endothelial cells (like transferrin or insulin receptors), they can hijack natural transcytosis pathways to gain entry into the brain parenchyma.
- Polymeric Nanoparticles: Made from biodegradable polymers like PLGA (poly(lactic-co-glycolic acid)), these can provide sustained release of a drug over weeks or months. Surface modification with peptides or antibodies allows for active targeting to specific brain regions or even cell types (e.g., neurons vs. microglia).
- Exosome-Based Delivery: Exosomes are natural, nanoscale vesicles released by cells for communication. We are pioneering the use of engineered exosomes, derived from patient's own cells, as biocompatible and non-immunogenic drug carriers that naturally cross biological barriers, including the BBB.
These nanocarriers can also be loaded with contrast agents, allowing us to track their distribution in real-time using MRI, ensuring they reach their intended target.
Long-Acting Implants and Injectable Depots
For conditions requiring stable, long-term medication (such as schizophrenia, severe bipolar disorder, or opioid use disorder), daily oral medication presents challenges with adherence and fluctuating blood levels. We are developing:
- Biodegradable Implantable Rods: Small, matchstick-sized implants placed subcutaneously that slowly erode, releasing a steady dose of medication (e.g., an antipsychotic or a buprenorphine analog) over 3-6 months. This eliminates the 'peak and trough' effect of pills, improving stability and preventing relapse due to missed doses.
- Injectable In Situ-Forming Depots: A liquid polymer-drug solution is injected subcutaneously or intramuscularly, where it solidifies into a gel-like depot that provides controlled release over weeks. This is less invasive than surgical implant placement.
Stimuli-Responsive and Closed-Loop Systems
The future of psychotropic delivery lies in 'smart' systems that release drugs on demand or in response to specific biological cues:
- Triggered Release: Nanoparticles can be designed to release their payload only when exposed to a specific external trigger, such as focused ultrasound (FUS) applied to a precise brain region, a near-infrared light pulse, or a shift in local pH (which occurs in areas of inflammation or tumor growth). This allows for spatiotemporally precise dosing.
- Closed-Loop 'Biofeedback' Systems: This is the holy grail of delivery. We are prototyping an implantable microdevice that continuously monitors a local biomarker—such as extracellular glutamate levels (a marker of stress/seizure) or local field potential patterns (indicative of an impending panic attack or depressive rumination). Upon detecting a pathological signature, the device automatically releases a microdose of a fast-acting therapeutic agent (like a GABA agonist or ketamine analog) to abort the episode before it fully manifests. This creates a brain-specific, responsive 'thermostat' for mood and neural stability.
These advanced delivery systems promise to increase efficacy, dramatically reduce side effects, improve patient compliance, and open the door to using powerful but short-acting or fragile compounds (like peptides or gene therapies) as practical psychiatric medicines. They represent a fundamental rethinking of how we interface pharmacotherapy with the dynamic, complex organ that is the brain.